We Are
a Professional
New Drug Development Team
Neupharma is
a professional new drug development team
formed by experts with extensive experience in the development,
approval, and launch of innovative medicines.
By bringing together knowledge from around the world,
we aim to drive a continuous stream of innovation from Japan,
delivering medicines that create true value for patients.
Our Story
Bringing Innovation to
Underdeveloped and Unresolved Areas of
Pharmaceuticals
There are still areas within the pharmaceutical industry where patient needs remain insufficiently addressed.
Some therapies are needed by patients but have not been brought to market under con-ventional pharmaceutical business models. Other medicines are already available over-seas but have not yet reached Japan.
At Neupharma, we believe that these under-developed and unresolved areas are precisely where new value in medicine can be created.
With flexible thinking and speed, we trans-form these areas into opportunities for in-novation.
That is the challenge Neupharma has taken on.
Maximizing the Value of Medicines
and Driving a Paradigm Shift in Treatment
What if a new medicine could dramatically exp-and treatment options?
What if a single drug discovery could move research forward in a disease area that had long remained stagnant?
What if medicines could go beyond treat-ment itself and become something that supports the way people live?
Such moments would open the way to the future of medicine.
They would represent a true paradigm shift in treatment.
To realize this kind of transformation, we build an integrated story across the entire process, from the discovery of promising drug seeds through development and market launch, and on to the post-launch sales structure.
By creating a value chain that maximizes the potential of each medicine, we ensure that its true value is delivered to patients, healthcare professionals, and all other stakeholders.
Our Business
Innovative. Unique.
A New Drug Development Model that Combines Speed with Feasibility
At the core of our new drug development model is
a unique and
highly practical approach powered by our global network.
Through this approach, we make it possible
to move from development to market launch
in a significantly shorter period than conventional models allow.
We also establish the systems needed to maximize post-launch
commercialization, including sales, marketing,
and logistics, creating a structure that enables
us to deliver new medicines faster and with greater certainty.
Repositioning Model
This is an approach in which drugs or drug candidates that have already been developed overseas, with confirmed efficacy and safety, are redeveloped for entirely different indications.
By significantly shortening development timelines and increasing the probability of success, this model makes it possible to create new value as innovative medicines.
Seed Discovery and
Commercialization Model
Through collaboration with research institu-tions, biotech companies, and pharmaceuti-cal companies around the world, we identify promising drug seeds with the potential to transform the future of medicine and devel-op them as new medicines in Japan.
By leveraging our proprietary global net-work, we access valuable drug seeds faster and more accurately than anyone else.
Seamless Collaboration
Together with partners
around the world,
we will continue to take on new
challenges for the future
through innovation.
Making 
the new standard.
Company
| Company Name | Neupharma Co., Ltd. |
|---|---|
| Head Office | PMO Takanawa Gateway, 2-19-17 Takanawa, Minato-ku, Tokyo, Japan |
| Established | October 2024 |
| Capital | JPY 15 million |
| Representative Director | Masanobu Kunishige |
| Employees | 41, as of March 2026 |
| Business Activities | Research, development, manufacturing, and sales of pharmaceutical products |
Contact
We are seeking partnerships
with a wide range of professionals.
If you would like to find out more about Neupharma,
collaborate on research and development,
or are
interested in forming an alliance,
please contact us here.